Articles

Understanding the role of derivatives in the economy and their potential impact in healthcare.

The ability to collect, analyze, report, and apply clinical and financial data is critical in today’s cancer care delivery. Clinical and financial metrics increasingly drive practice performance and reputation and facilitate success in revenue achievement in a world that values improved quality and improved efficiency through cost benchmarking.

A majority of value-based arrangements don’t address the stakeholder at the center of the issue – the patient. It’s time for that to change. In this panel we will discuss how innovative oncology contracts can be constructed to directly address both payers’ and patients’ concerns about financial and clinical uncertainty.

As the healthcare industry continues its transition away from traditional fee-for-service models to a more value-based model, several successful models are not only including providers and payers, but also pharma manufacturers, understanding that for many conditions, the drug is a significant part of total cost of care.

We're in a time of significant macroeconomic uncertainty, driven by inflation and also by its potential unemployment and recessionary impact. History tells us that periods of significant economic upheaval have had significant long-term effects on the healthcare system.

With 75% of the pharmaceutical research and development focused on cancer drug development, this panel will explore and summarize the near-term innovative drugs and gene therapies coming to market in the next year. Additionally, the panel will provide an assessment on the impact and trends on the new cancer drug technologies and label expansions will have on the cancer care ecosystem.

The past two years have been extremely disruptive to all stakeholders in the cancer care ecosystem, especially patients who have forgone cancer screenings. The impact of the past two years along with emerging new technologies continue to transform the cancer care economic reality. In this session, key real-world data, metrics, and insights will be shared to help us better understand what the next 12-month forecast will be given the continued, situational impact of the past two years.

This panel will discuss how clinicians can help impact cancer care.

The industry continues to explore value-based payment models in its efforts to shift away from fee-for-service. One of those payment models is bundled payments – which can center on specific treatment modalities, such as surgery or chemotherapy, or entire episodes of care.

Key thought leaders will focus on financial toxicity, discuss their perspectives and share future-looking patient centered solutions to address access issues.